Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 1,142,160 $ 4,570,562 $ 5,658,127 $ 9,702,978
General and administrative 1,375,380 1,483,573 4,729,969 5,154,324
Total operating expenses 2,517,540 6,054,135 10,388,096 14,857,302
Loss from operations (2,517,540) (6,054,135) (10,388,096) (14,857,302)
Other income (expense):        
Change in fair value of financial instruments 119,019 61,407 683,568 2,972,272
Other interest expense (75,413)   (124,595)  
Interest expense on convertible debt       (282,064)
Gain on extinguishment of convertible debt and derivative liability       1,307,421
Other income 113,286 35,853 197,070 62,915
Total other income (expense), net 156,892 97,260 756,043 4,060,544
Net loss (2,360,648) (5,956,875) (9,632,053) (10,796,758)
Other comprehensive loss        
Foreign currency translation adjustment   (131,874) (175,815) (82,397)
Comprehensive loss $ (2,360,648) $ (6,088,749) $ (9,807,868) $ (10,879,155)
Net loss per share, basic $ (0.19) $ (0.83) $ (0.98) $ (1.50)
Net loss per share, diluted $ (0.19) $ (0.83) $ (0.98) $ (1.50)
Weighted-average shares outstanding of common shares, basic 12,370,830 7,195,529 9,861,719 7,195,529
Weighted-average shares outstanding of common shares, diluted 12,370,830 7,195,529 9,861,719 7,195,529